NCT06184126 Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises
| NCT ID | NCT06184126 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Maryland, Baltimore |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-11-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.
Eligibility Criteria
Inclusion Criteria: * Adult (age \> 18 years) emergency department patient * History of sickle cell disease * Presenting to the emergency department due to acute pain related to sickle cell disease thought to be due to vaso-occlusive crisis Exclusion Criteria: * Prior enrollment in this study * Presenting with a chief complaint suggestive of a complicated crisis (such as concern for acute chest syndrome, splenic sequestration, hepatic sequestration, pulmonary embolism) as determined by the clinical care provider * Not being treated with intravenous opioids for the vaso-occlusive crisis * Patients who lack the capacity to provide informed consent * Medical history of seizures or known intolerance to virtual reality * Disabilities like vision and hearing defects etc. that preclude the use of a head mounted virtual reality device. * Known to be pregnant * Incarcerated at the time of evaluation * Over the age of 89 years old
Contact & Investigator
R. Gentry Wilklerson, MD
PRINCIPAL INVESTIGATOR
U of Maryland, Baltimore
Frequently Asked Questions
Who can join the NCT06184126 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06184126 currently recruiting?
Yes, NCT06184126 is actively recruiting participants. Contact the research team at gwilkerson@som.umaryland.edu for enrollment information.
Where is the NCT06184126 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06184126 clinical trial?
NCT06184126 is sponsored by University of Maryland, Baltimore. The principal investigator is R. Gentry Wilklerson, MD at U of Maryland, Baltimore. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.